Treating Acute Leukemias
in Latin America

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases

Overview

This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of leukemia patients, join patient case-based discussions, and interact with experts.

Date and Location

October 19–20, 2023, Webinar

Meeting Content

View the slides and watch the video of Day 1

View the slides and watch the video of Day 2

Co-Chairs

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX, USA

Faculty

Roberta Demichelis

Roberta Demichelis, MD

Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Zubirán,
Mexico

Wellington Silva

Wellington Silva, MD

Hospital Regional de São José,
Brazil

Phillip Sheinberg

Phillip Scheinberg, MD, PhD

Hospital de São José, Beneficencia Portuguesa de São Paulo,
Brazil

José Maria Ribera

Josep-Maria Ribera, MD, PhD

Catalan Institute of Oncology,
University Hospital Germans Trias i Pujol,
Spain

Agenda

This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within the LATAM region.

Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the LATAM region.

Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment.

Day 1: Plenary Sessions

Thursday, October 19, 2023

4.00 PM – 7.00 PM (UTC -6) Mexico City
5.00 PM – 8.00 PM (UTC -5) Houston/Bogota
7.00 PM – 10.00 PM (UTC -3) Brasilia/Buenos Aires

Time (UTC-3) Topic Presenter
7.00 PM – 7.10 PM Welcome and meeting overview Elias Jabbour
7.10 PM – 7.25 PM Review of prognostic value of MRD in ALL and AML Phillip Scheinberg
7.25 PM – 7.40 PM Latest achievements and developments in ALL and AML Elias Jabbour
7.40 PM – 7.50 PM Best practices for first-line treatment in ALL Josep-Maria Ribera
7.50 PM – 8.05 PM AYA ALL patients: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Wellington Silva
8.05 PM – 8.35 PM

ALL case-based panel discussion

  • Case ALL: elderly/frail (10 min)
  • Case ALL: AYA (10 min)
  • Discussion (10 min) – panelists: all faculty
Roberta Demichelis (local cases),
Elias Jabbour, and all faculty
8.35 PM – 8.45 PM Break  
8.45 PM – 9.10 PM Genetic characterization and risk stratification of AML; role of FLT3 and IDH in AML and ​Special considerations for young and fit patients​ Naval Daver
9.10 PM – 9.25 PM Therapeutic approaches in high-risk and frail AML patients​ Phillip Scheinberg
9.25 PM – 9.50 PM Panel discussion: Open questions in ALL and AML – regional challenges (transplant, CAR T, studies, and other)​ Elias Jabbour and all faculty​
(present 2–3 slides as trigger)​
9.50 PM – 10.00 PM Session close​)​ Elias Jabbour and all faculty​
(present 2–3 slides as trigger)​Elias Jabbour​

Day 2: Plenary Sessions

Friday, October 20, 2023

4.00 PM – 7.00 PM (UTC -6) Mexico City
5.00 PM – 8.00 PM (UTC -5) Houston/Bogota
7.00 PM – 10.00 PM (UTC -3) Brasilia/Buenos Aires

Time (UTC-3) Topic Presenter
7.00 PM – 7.10 PM Welcome to Day 2 Naval Daver
7.10 PM – 7.30 PM Current treatment options for relapsed ALL in adult and elderly patients Elias Jabbour
7.30 PM – 7.50 PM Current treatment options for relapsed AML in adult and elderly patients Naval Daver
7.50 PM – 8.20 PM

AML case-based panel discussion

  • Case AML: young, high risk (10 min)
  • Case AML: elderly (10 min)
  • Discussion (10 min)
Roberta Demichelis (local cases), Naval Daver, and all faculty
8.20 PM – 8.30 PM Break  
8.30 PM – 8.50 PM Long-term safety considerations for leukemias Josep-Maria Ribera
8.50 PM – 9.10 PM Current and future role of transplantation in acute leukemias in Latin America Wellington Silva
9.10 PM – 9.50 PM

Panel discussion: How treatment in first line influences further approaches in ALL and AML

  • Will CAR T and bispecifics change the treatment landscape?
  • Role of HSCT – is it still necessary?
  • What does the future look like? Adoption of therapies and evolving standards of care in LATAM
Elias Jabbour, Naval Daver, and all faculty
9.50 PM – 10.00 PM Session close Elias Jabbour